Cargando…

Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients

Cancer genome profiling (CGP) occasionally identifies pathogenic germline variants (PGV) in cancer susceptibility genes (CSG) as secondary findings. Here, we analyzed the prevalence and clinical characteristics of PGVs based on nationwide real-world data from CGP tests in Japan. We analyzed the geno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Satake, Tomoyuki, Kondo, Shunsuke, Tanabe, Noriko, Mizuno, Takaaki, Katsuya, Yuki, Sato, Jun, Koyama, Takafumi, Yoshida, Tatsuya, Hirata, Makoto, Yamamoto, Noboru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644847/ https://www.ncbi.nlm.nih.gov/pubmed/37916805 http://dx.doi.org/10.1158/2767-9764.CRC-23-0018

Ejemplares similares

Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials
por: Takamizawa, Shigemasa, et al.
Publicado: (2022)

Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China
por: Mizuno, Takaaki, et al.
Publicado: (2022)

Practical consideration for successful sequential tumor biopsies in first-in-human trials
por: Koyama, Takafumi, et al.
Publicado: (2022)

Prevalence of psychological distress, quality of life, and satisfaction among patients and family members following comprehensive genomic profiling testing: Protocol of the Quality of life for Cancer genomics and Advanced Therapeutics (Q-CAT) study
por: Nishino, Makoto, et al.
Publicado: (2023)

Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital
por: Uehara, Yuji, et al.
Publicado: (2023)

Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients
por: Lee, Daphne SC, et al.
Publicado: (2012)

Germline BRCA2 and somatic P53 alterations in male breast cancer
por: Csokay, B, et al.
Publicado: (2000)

Myxofibrosarcoma harboring an MLH1 pathogenic germline variant associated with Muir-Torre syndrome: a case report
por: Nakagawa, Makoto, et al.
Publicado: (2021)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations
por: Wang-Gohrke, S, et al.
Publicado: (1999)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants
por: Inagaki-Kawata, Yukiko, et al.
Publicado: (2020)

BRCA1 and BRCA2 germline mutation analysis in the Indonesian population
por: Purnomosari, Dewajani, et al.
Publicado: (2007)

Comprehensive Analysis of BRCA1, BRCA2 and TP53 Germline Mutation and Tumor Characterization: A Portrait of Early-Onset Breast Cancer in Brazil
por: Carraro, Dirce Maria, et al.
Publicado: (2013)

Germline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: characterizing a Northeast Brazilian Population
por: Felix, Gabriela ES, et al.
Publicado: (2014)

Evaluation of models to predict BRCA germline mutations
por: Kang, H H, et al.
Publicado: (2006)

The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population
por: Stegel, Vida, et al.
Publicado: (2011)

Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations
por: Kim, Jinyong, et al.
Publicado: (2023)

Contribution of BRCA1 and BRCA2 Germline Mutations to Early Algerian Breast Cancer
por: Henouda, Sarra, et al.
Publicado: (2016)

BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
por: Vos, Shoko, et al.
Publicado: (2017)

Melanoma predisposition—A limited role for germline BRCA1 and BRCA2 variants
por: Adams, David J., et al.
Publicado: (2019)

Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland
por: Złowocka-Perłowska, Elżbieta, et al.
Publicado: (2022)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

Pathogenic Germline BRCA1/2 Mutations and Familial Predisposition to Gastric Cancer
por: Ichikawa, Hiroshi, et al.
Publicado: (2018)

Germline BRCA2 mutations in men with breast cancer.
por: Mavraki, E., et al.
Publicado: (1997)

BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored
por: Crocetto, Felice, et al.
Publicado: (2021)

Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer
por: Goffin, J R, et al.
Publicado: (2003)

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
por: Ligtenberg, M J L, et al.
Publicado: (1999)

Nipple aspiration and ductal lavage in women with a germline BRCA1 or BRCA2 mutation
por: Mitchell, Gillian, et al.
Publicado: (2005)

Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India
por: Saxena, Sunita, et al.
Publicado: (2006)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

BRCA1 and BRCA2 Germline Mutations Screening in Algerian Breast/Ovarian Cancer Families
por: Cherbal, Farid, et al.
Publicado: (2010)

Germline Mutations in BRCA1 and BRCA2 in Polish Families Predisposed to Breast and Ovary Cancers
por: Grzybowska, E., et al.
Publicado: (1999)

Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations
por: Phillips, Kelly-Anne, et al.
Publicado: (2016)

Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients
por: Torres, D., et al.
Publicado: (2017)

Novel Germline Mutations of BRCA1 and BRCA2 in Korean Familial Breast Cancer Patients
por: Kim, Hee Nam, et al.
Publicado: (2019)

Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants
por: Edaily, Sarah, et al.
Publicado: (2022)

First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors
por: Iwasa, Satoru, et al.
Publicado: (2022)

Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
por: Kondo, Shunsuke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l1te3kr6k6qsf87vq68c8dtmqd